Injectable "Satellite Livers" — MIT's Breakthrough Could Replace Liver Transplants

More than 10,000 Americans are on the liver transplant waitlist at any given time, and many are too sick for surgery. A new approach from MIT lets doctors inject tiny liver tissue grafts instead — no surgery required.

The liver performs roughly 500 essential functions, from filtering toxins to regulating blood clotting and metabolizing drugs. When it fails, the only reliable treatment today is a surgical transplant — but donated organs are scarce, and many patients are not healthy enough to survive the operation. A team of engineers at MIT, led by Professor Sangeeta Bhatia, has developed a radically different solution: injectable "satellite livers."

The approach uses hydrogel microspheres — tiny, uniform beads that behave like a liquid when packed together — mixed with liver cells called hepatocytes and supportive fibroblast cells. The mixture is injected through a syringe into the fatty tissue of the abdomen, guided by ultrasound. Once inside the body, the microspheres regain their solid structure, creating a stable niche where the liver cells can connect to nearby blood vessels and begin functioning. In a study published in Cell Biomaterials, the researchers showed that these mini livers remained viable in mice for at least two months, producing the enzymes and proteins a healthy liver would.

Three things worth knowing:

The team used a microfluidic device to manufacture hydrogel microspheres of precise, uniform size — a key engineering detail that ensures the cells pack together consistently and integrate with the host's circulatory system.
Ultrasound serves double duty: it guides the injection in real time, and afterward, it lets doctors noninvasively monitor the graft's long-term stability without any additional procedures.
While the current study targeted the abdominal fat tissue, the researchers envision future grafts placed in the spleen or near the kidneys — anywhere with sufficient space and blood supply. The approach could eventually treat not just liver failure but also enzyme deficiencies and metabolic disorders.

The work is still in animal trials, but if it translates to humans, injectable satellite livers could transform the treatment of liver disease — one of the top ten causes of death worldwide — from a surgical crisis into an outpatient procedure.